重复的多领域认知训练可以防止在老鼠阿尔茨海默病模型中发现的认知衰退,焦虑和粉样蛋白病理
Jogender Mehla1,2, Scott H Deibel1,3, Hadil Karem1
1Canadian Centre for Behavioural Neuroscience, University of Lethbridge, Lethbridge, AB, Canada.
Communications biology
|November 10, 2023
概括
多领域认知训练改善了认知功能,并减少了阿尔茨海默氏症.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 认知科学 认知科学
背景情况:
- 生活方式因素,如教育和活动,有利于老化中的认知功能.
- 这些因素可能会延迟神经退行性疾病,如阿尔茨海默病.
研究的目的:
- 研究认知训练对阿尔茨海默病病理学的保护作用.
- 为了比较单域与多域认知训练的有效性.
主要方法:
- APPNL-G-F/NL-G-F小鼠在3,6和9个月大时接受了单或多域认知训练.
- 培训包括空间导航,物体识别和恐惧调节.
- 认知功能,大脑病理和焦虑行为在12个月后被评估.
主要成果:
- 多领域训练改善了认知功能,减少了粉样蛋白负载和微质化,并保留了APP小鼠的胆固醇功能.
- 单域训练显示微质瘤的轻微减少.
- 多领域训练也改善了类似焦虑的行为.
结论:
- 多领域认知训练为缓解阿尔茨海默病认知缺陷提供了潜在的好处.
- 这些发现为认知训练的治疗作用提供了因果证据.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.5K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
相关概念视频
01:26Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
01:22Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197